April 2, 2012

Tokyo, Japan, April 2, 2012 --- Kyowa Hakko Kirin Co., Ltd. ("Kyowa Hakko Kirin") announces that it will submit on the application in Japan for the marketing approval of KW-6002 (Istradefylline), which is currently undergoing development for the treatment of Parkinson's disease, has been submitted on March 30, 2012.

KW-6002 is a selective antagonist of adenosine A2A receptors. Kyowa Hakko Kirin has been developing KW-6002 as anti-Parkinson's disease drug with a novel mechanism of action. The outcomes from Japanese clinical trials conducted so far have demonstrated the efficacy and tolerability of KW-6002 in Parkinson's disease patients receiving levodopa therapy.

Kyowa Hakko Kirin believes that KW-6002 provides a new treatment option that is potentially useful in the treatment of Parkinson's disease.

distributed by

This press release was issued by Kyowa Hakko Kirin Co. Ltd. and was initially posted at http://www.kyowa-kirin.co.jp/english/news/2012/e20120402_01.html . It was distributed, unedited and unaltered, by noodls on 2012-04-02 04:49:12 AM. The issuer is solely responsible for the accuracy of the information contained therein.